Physiologically-based pharmacokinetic modelling to identify physiological and molecular characteristics driving variability in drug exposure

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Prospectively defining the physiological and molecular characteristics most likely driving between-subject variability (BSV) in drug exposure provides the opportunity to inform the assessment of biomarkers to account for this variability. A physiologically based pharmacokinetic (PBPK) model was constructed and verified for dabrafenib. This model was then used to evaluate the physiological and molecular characteristics driving BSV in dabrafenib exposure. The capacity to discriminate a steady-state dabrafenib trough concentration >48 ng/mL was also evaluated. The mean simulated/observed ratios for the parameters describing dabrafenib exposure in single-dose, multiple-dose, and drug–drug interaction studies were between 0.78 and 1.23. Multivariable analysis indicated that consideration of baseline weight, body mass index, and CYP2C8, CYP3A4, and P-gp abundance strongly predicts steady-state dabrafenib trough concentration above 48 ng/mL (ROC AUC = 0.94; accuracy = 86%). This is the first study to use a verified PBPK model to identify baseline physiological and molecular characteristics driving BSV in drug exposure.

Original languageEnglish
Pages (from-to)1219-1228
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume104
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Physiologically-based pharmacokinetic modelling to identify physiological and molecular characteristics driving variability in drug exposure'. Together they form a unique fingerprint.

  • Cite this